According to a recent LinkedIn post from Latigo Biotherapeutics, the company is adding Neha Krishnamohan as chief financial officer and chief business officer. The post highlights her more than 15 years of experience in healthcare investment banking and biotech finance, including senior roles at Artiva Biotherapeutics and Kinnate Biopharma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post notes that Krishnamohan played a lead role in Artiva’s transition to the public markets and previously worked in healthcare investment banking and M&A at Goldman Sachs. This background may position Latigo to refine its capital strategy, explore strategic transactions, and potentially prepare for future financing or public-market opportunities.
By emphasizing her dual remit over finance and corporate development, the post suggests Latigo is prioritizing both balance sheet management and business development. For investors, this move could indicate a focus on deal-making, partnerships, or scaling initiatives aligned with the company’s differentiated, non-opioid pain pipeline.
The reference to advancing its non-opioid pain pipeline underscores Latigo’s positioning in a therapeutic area with ongoing demand for alternatives to traditional pain management. Strengthened financial and corporate development leadership may enhance the company’s ability to fund clinical progress, pursue collaborations, and compete within the broader biopharma and pain-treatment landscape.